Two Clinical Cases of adjunctive use of an SGLT-2 Inhibitor in Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) prevalence is increasing and despite all available modern treatment options, an overall small but noticeable increase of mean HbA1c was recently observed in various registries. Authorized adjunctive pharmacological treatment options to insulin therapy are still scarce for T1DM. In February 2019, the European Medicines Agency (EMA) approved dapagliflozin as the first in class sodium/glucose co-transporter 2 inhibitor (SGLT-2i) adjunctive therapy to insulin in patients with T1DM, which is currently still not approved by the FDA in the United States.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Thorsten Siegmund, Francisco Javier Ampudia-Blasco, Oliver Schnell Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | European Medicines Agency (EMA) | Forxiga | Insulin | Sodium | USA Health